Effects of Dietary Phytoestrogens on Hormones Throughout A

Total Page:16

File Type:pdf, Size:1020Kb

Effects of Dietary Phytoestrogens on Hormones Throughout A nutrients Review Effects of Dietary Phytoestrogens on Hormones throughout a Human Lifespan: A Review Inés Domínguez-López 1 , Maria Yago-Aragón 1, Albert Salas-Huetos 2 , Anna Tresserra-Rimbau 1,3,4,5,* and Sara Hurtado-Barroso 1,3 1 Department of Nutrition, Food Science and Gastronomy, XaRTA, INSA, School of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain; [email protected] (I.D.-L.); [email protected] (M.Y.-A.); [email protected] (S.H.-B.) 2 Andrology and IVF Laboratory, Division of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT 84108, USA; [email protected] 3 Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain 4 Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain 5 Institut d’Investigació Sanitària Pere Virgili (IISPV), 43201 Reus, Spain * Correspondence: [email protected] Received: 7 July 2020; Accepted: 12 August 2020; Published: 15 August 2020 Abstract: Dietary phytoestrogens are bioactive compounds with estrogenic activity. With the growing popularity of plant-based diets, the intake of phytoestrogen-rich legumes (especially soy) and legume-derived foods has increased. Evidence from preclinical studies suggests these compounds may have an effect on hormones and health, although the results of human trials are unclear. The effects of dietary phytoestrogens depend on the exposure (phytoestrogen type, matrix, concentration, and bioavailability), ethnicity, hormone levels (related to age, sex, and physiological condition), and health status of the consumer. In this review, we have summarized the results of human studies on dietary phytoestrogens with the aim of assessing the possible hormone-dependent outcomes and health effects of their consumption throughout a lifespan, focusing on pregnancy, childhood, adulthood, and the premenopausal and postmenopausal stages. In pregnant women, an improvement of insulin metabolism has been reported in only one study. Sex hormone alterations have been found in the late stages of childhood, and goitrogenic effects in children with hypothyroidism. In premenopausal and postmenopausal women, the reported impacts on hormones are inconsistent, although beneficial goitrogenic effects and improved glycemic control and cardiovascular risk markers have been described in postmenopausal individuals. In adult men, different authors report goitrogenic effects and a reduction of insulin in non-alcoholic fatty liver patients. Further carefully designed studies are warranted to better elucidate the impact of phytoestrogen consumption on the endocrine system at different life stages. Keywords: isoflavones; soy; dietary flavonoids; lignans; flaxseeds; endocrine; stages of life; estrogenic; polyphenols; health 1. Introduction Phytoestrogens are polyphenolic molecules with a structural similarity to endogenous human hormones, hence their estrogenic activity. The main dietary source of these plant secondary metabolites is legumes (particularly soy), and to a lesser extent fruits, vegetables, and cereals [1]. Figure1 shows the most common phytoestrogens in diet. According to their origin, lignins are classified into plant lignans (e.g., pinoresinol, secoisolariciresinol, matairesinol, and sesamin) and enterolignans (e.g., enterodiol Nutrients 2020, 12, 2456; doi:10.3390/nu12082456 www.mdpi.com/journal/nutrients Nutrients 2020, 12, 2456 2 of 25 Nutrients 2020, 12, x FOR PEER REVIEW 2 of 25 andintestinal enterolactone), bacteria [1]. which Although are metabolized ingested from in lower plant lignansquantities by intestinalthan isoflavones bacteria [1and]. Although lignans, ingestedprenylflavonoids in lower quantitiesfrom beer than and isoflavones coumestans and from lignans, soy prenylflavonoids are also regarded from as beer polyphenols and coumestans with fromestrogenic soy are activity. also regarded as polyphenols with estrogenic activity. Figure 1. Classification and examples of the most common dietary phytoestrogens. Images are the chemicalFigure 1. structuresClassification of genistein, and examples coumestrol, of the andmost enterodiol. common dietary phytoestrogens. Images are the chemical structures of genistein, coumestrol, and enterodiol. The intake of phytoestrogens has increased due to the widespread use of soy products for human consumptionThe intake and of asphytoestrogens cattle food [2 ].has In increased Europe, the due lowest to the averagewidespread intake use of of phytoestrogens soy products for occurs human in Mediterraneanconsumption and countries, as cattle whereas food [2]. consumption In Europe, the in Northernlowest average countries intake is 0.76of phytoestrogens mg/day [3]. The occurs highest in soy-derivedMediterranean isoflavone countries, intakes whereas worldwide consumption are still in in Nort Chinahern and countries Japan, where is 0.76 the mg/day population [3]. The consumes highest ansoy-derived average of isoflavone 15–50 mg intakes per day, worldwide compared toare only still about in China 2 mg and per dayJapan, in Westernwhere the countries population [4,5]. Theconsumes promising an average health of eff 15–50ects of mg soy per have day, driven compared some to people only about in developed 2 mg per countries day in Western to consume countries it as an[4,5]. alternative The promising to meat health or dairy effects products. of soy have driven some people in developed countries to consume it as anDietary alternative phytoestrogens to meat or aredairy digested products. in the small intestine, where they are poorly absorbed. ThoseDietary that reach phytoestrogens the liver are conjugatedare digested and in circulate the smal inl theintestine, plasma where until excretion they arein poorly urine. absorbed. Thos that areThose not that absorbed reach arethe metabolized liver are conjugated by the gut and microbiota circulate into in lowerthe plasma weight until compounds excretion [1 in]. Theurine. diversity Those ofthat food are matricesnot absorbed (from are pure metabolized compounds by to the complex gut microbiota foods) used into in lower clinical weight studies compounds could also [1]. lead The to didiversityfferent results of food although matrices interindividual (from pure compounds variability seems to complex more determinant. foods) used Itin has clinical been demonstratedstudies could thatalso phytoestrogenlead to different extraction results although from complex interindividual food matrices, variability such seems as those more with determinant. high content It ofhas sugars been anddemonstrated proteins, is that more phytoestrogen difficult in in vitroextractionstudies; from however, complex no clearfood dimatrices,fferences such regarding as those food with matrices high werecontent observed of sugars in humansand proteins, [6]. Nevertheless, is more difficult results in in using vitro pure studies; compounds however, must no clear be extrapolated differences carefullyregarding because food matrices not only were is observed the matrix in dihumansfferent, [6]. but Nevertheless, also the concentration, results using which pure iscompounds higher in puremust extracts.be extrapolated carefully because not only is the matrix different, but also the concentration, whichResults is higher from in humanpure extracts. studies suggest that phytoestrogens may lower the risk of osteoporosis, someResults cardiometabolic from human diseases, studies cognitive suggest dysfunction,that phytoestrogens breast and may prostate lower cancer,the risk and of osteoporosis, menopausal symptomssome cardiometabolic by modulating diseases, the endocrine cognitive system dysfunctio (Figure2).n, However, breast and some prostate authors cancer, describe and phytoestrogens menopausal assymptoms endocrine by disruptors modulating and believe the endocrine their beneficial system effects (Figure have been 2). overestimatedHowever, some[2,5 ,7authors]. This ambiguity describe couldphytoestrogens be partially as dueendocrine to the disruptors variability and of published believe their studies, beneficial as the effects beneficial have or been harmful overestimated effects of phytoestrogens[2,5,7]. This ambiguity depend could on the be partially exposure due (type, to the amount variability consumed, of published and bioavailability), studies, as the beneficial ethnicity, hormonalor harmful status effects (age of and phytoestrogens sex and physiological depend condition), on the exposure and health (type, status amount of the consumerconsumed, [2 ,5and,7]. bioavailability), ethnicity, hormonal status (age and sex and physiological condition), and health status of the consumer [2,5,7]. Nutrients 2020, 12, 2456 3 of 25 Nutrients 2020, 12, x FOR PEER REVIEW 3 of 25 FigureFigure 2.2. Summary of potentialpotential healthhealth outcomesoutcomes ofof phytoestrogensphytoestrogens through thethe modulationmodulation ofof thethe endocrineendocrine systemsystem inin ((aa)) thyroids,thyroids, ((bb)) liver,liver, ((cc)) ovaries,ovaries, ((dd)) bones,bones, ((ee)) hypothalamic–pituitary–gonadalhypothalamic–pituitary–gonadal axis,axis, ((ff)) pancreas,pancreas, ((gg)) fatfat tissue, (h) prostate. FSH: FSH: follicle-stimulating follicle-stimulating hormone; hormone; GnRH: GnRH: gonadotropin- gonadotropin- releasingreleasing hormone; IGF-1: IGF-1: insulin insulin growth growth factor factor 1; 1;LH: LH: luteinizing luteinizing hormone; hormone; OC: OC:osteocalcin;
Recommended publications
  • Pinoresinol Reductase 1 Impacts Lignin Distribution During Secondary Cell Wall Biosynthesis in Arabidopsis
    Phytochemistry xxx (2014) xxx–xxx Contents lists available at ScienceDirect Phytochemistry journal homepage: www.elsevier.com/locate/phytochem Pinoresinol reductase 1 impacts lignin distribution during secondary cell wall biosynthesis in Arabidopsis Qiao Zhao a, Yining Zeng b,e, Yanbin Yin c, Yunqiao Pu d,e, Lisa A. Jackson a,e, Nancy L. Engle e,f, Madhavi Z. Martin e,f, Timothy J. Tschaplinski e,f, Shi-You Ding b,e, Arthur J. Ragauskas d,e, ⇑ Richard A. Dixon a,e,g, a Plant Biology Division, Samuel Roberts Noble Foundation, 2510 Sam Noble Parkway, Ardmore, OK 73401, USA b Biosciences Center, National Renewable Energy Laboratory, Golden, CO 80401, USA c Department of Biological Sciences, Northern Illinois University, DeKalb, IL 60115, USA d Institute of Paper Science and Technology, Georgia Institute of Technology, Atlanta, GA, USA e BioEnergy Science Center (BESC), Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA f Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA g Department of Biological Sciences, University of North Texas, Denton, TX 76203, USA article info abstract Article history: Pinoresinol reductase (PrR) catalyzes the conversion of the lignan (À)-pinoresinol to (À)-lariciresinol in Available online xxxx Arabidopsis thaliana, where it is encoded by two genes, PrR1 and PrR2, that appear to act redundantly. PrR1 is highly expressed in lignified inflorescence stem tissue, whereas PrR2 expression is barely detect- Keywords: able in stems. Co-expression analysis has indicated that PrR1 is co-expressed with many characterized Lignan genes involved in secondary cell wall biosynthesis, whereas PrR2 expression clusters with a different Lignin set of genes.
    [Show full text]
  • Nutraceuticals Brian Lockwood
    CjigVXZji^XVah HZXdcYZY^i^dc 7g^VcAdX`lddY 00 Prelim 2/3/07 18:51 Page i Nutraceuticals 00 Prelim 2/3/07 18:51 Page ii 00 Prelim 2/3/07 18:51 Page iii Nutraceuticals A guide for healthcare professionals Second edition Brian Lockwood BPharm, PhD, MRPharmS Senior Lecturer in Pharmacy, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK London • Chicago 00 Prelim 2/3/07 18:51 Page iv Published by the Pharmaceutical Press An imprint of RPS Publishing 1 Lambeth High Street, London SE1 7JN, UK 100 South Atkinson Road, Suite 200, Grayslake, IL 60030–7820, USA © Pharmaceutical Press 2007 is a trade mark of RPS Publishing RPS Publishing is the publishing organisation of the Royal Pharmaceutical Society of Great Britain First edition published 2002 Second edition published 2007 Typeset by Type Study, Scarborough, North Yorkshire Printed in Great Britain by TJ International, Padstow, Cornwall ISBN 978 0 85369 659 9 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of Brian Lockwood to be identified as the author of this work has been asserted by him in accordance with sections 77 and 78 and subject to section 79(6) of the Copyright, Designs and Patents Act, 1988.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    Confidential Clinical study protocol number: J1228 Page 1 Version Date: May 7, 2018 IRB study Number: NA_00067315 A Trial of maintenance Rituximab with mTor inhibition after High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin’s Lymphoma Principal Investigator: Douglas E. Gladstone, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1650 Orleans Street, CRBI-287 Baltimore, MD 21287 Phone: 410-955-8781 Fax: 410-614-1005 Email: [email protected] IRB Protocol Number: NA_00067315 Study Number: J1228 IND Number: EXEMPT Novartis Protocol Number: CRAD001NUS157T Version: May 7, 2018 Co-Investigators: Jonathan Powell 1650 Orleans Street, CRBI-443 Phone: 410-502-7887 Fax: 443-287-4653 Email: [email protected] Richard Jones 1650 Orleans Street, CRBI-244 Phone: 410-955-2006 Fax: 410-614-7279 Email: [email protected] Confidential Clinical study protocol number: J1228 Page 2 Version Date: May 7, 2018 IRB study Number: NA_00067315 Satish Shanbhag Johns Hopkins Bayview Medical Center 301 Building, Suite 4500 4940 Eastern Ave Phone: 410-550-4061 Fax: 410-550-5445 Email: [email protected] Statisticians: Gary Rosner Phone: 410-955-4884 Email: [email protected] Marianna Zahurak Phone: 410-955-4219 Email: [email protected] Confidential Clinical study protocol number: J1228 Page 3 Version Date: May 7, 2018 IRB study Number: NA_00067315 Table of contents Table of contents ......................................................................................................................... 3 List of abbreviations
    [Show full text]
  • Memorandum Date: June 6, 2014
    DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Memorandum Date: June 6, 2014 From: Bisphenol A (BPA) Joint Emerging Science Working Group Smita Baid Abraham, M.D. ∂, M. M. Cecilia Aguila, D.V.M. ⌂, Steven Anderson, Ph.D., M.P.P.€* , Jason Aungst, Ph.D.£*, John Bowyer, Ph.D. ∞, Ronald P Brown, M.S., D.A.B.T.¥, Karim A. Calis, Pharm.D., M.P.H. ∂, Luísa Camacho, Ph.D. ∞, Jamie Carpenter, Ph.D.¥, William H. Chong, M.D. ∂, Chrissy J Cochran, Ph.D.¥, Barry Delclos, Ph.D.∞, Daniel Doerge, Ph.D.∞, Dongyi (Tony) Du, M.D., Ph.D. ¥, Sherry Ferguson, Ph.D.∞, Jeffrey Fisher, Ph.D.∞, Suzanne Fitzpatrick, Ph.D. D.A.B.T. £, Qian Graves, Ph.D.£, Yan Gu, Ph.D.£, Ji Guo, Ph.D.¥, Deborah Hansen, Ph.D. ∞, Laura Hungerford, D.V.M., Ph.D.⌂, Nathan S Ivey, Ph.D. ¥, Abigail C Jacobs, Ph.D.∂, Elizabeth Katz, Ph.D. ¥, Hyon Kwon, Pharm.D. ∂, Ifthekar Mahmood, Ph.D. ∂, Leslie McKinney, Ph.D.∂, Robert Mitkus, Ph.D., D.A.B.T.€, Gregory Noonan, Ph.D. £, Allison O’Neill, M.A. ¥, Penelope Rice, Ph.D., D.A.B.T. £, Mary Shackelford, Ph.D. £, Evi Struble, Ph.D.€, Yelizaveta Torosyan, Ph.D. ¥, Beverly Wolpert, Ph.D.£, Hong Yang, Ph.D.€, Lisa B Yanoff, M.D.∂ *Co-Chair, € Center for Biologics Evaluation & Research, £ Center for Food Safety and Applied Nutrition, ∂ Center for Drug Evaluation and Research, ¥ Center for Devices and Radiological Health, ∞ National Center for Toxicological Research, ⌂ Center for Veterinary Medicine Subject: 2014 Updated Review of Literature and Data on Bisphenol A (CAS RN 80-05-7) To: FDA Chemical and Environmental Science Council (CESC) Office of the Commissioner Attn: Stephen M.
    [Show full text]
  • What Are Soy Isoflavones? Figure 2: Soy Isoflavones Reduced Plasma Isoprostanes Soy Isoflavones Are a Class of Natural Bioactive Compounds in Soybeans
    TECHNICAL REPORT Purina Veterinary Diets® OM Overweight Management® brand canine dry formula and the Beneficial Role of Isoflavones Introduction Approximately 35% of adult dogs in the U.S. are overweight or obese1. A markedly greater incidence of overweight and obesity was observed in neutered male (59% higher) and female dogs (40% higher)1. Chronic obesity can increase the risk of, or complications from, several chronic diseases including diabetes, hypertension, pulmonary and cardiovascular disease, and degenerative joint disease2. Obesity produces chronic, mild inflammation and increases oxidative stress, which, in turn, contributes to the development of the above-mentioned chronic diseases.3,4 Therefore, reducing obesity and oxidative stress can promote a long life span and improved quality of life in dogs. What are Soy Isoflavones? Figure 2: Soy Isoflavones Reduced Plasma Isoprostanes Soy isoflavones are a class of natural bioactive compounds in soybeans. Natural a Marker of Oxidative Stress soy isoflavones include three chemical compounds: daidzein, genistein, 5 Plasma Isoprostanes (ng/ml) and glycitein. Many health benefits have been associated with regular consumption of soy products. In humans, soy has been found to reduce the 4 risk of cardiovascular disease and certain types of cancer (breast and prostate cancer); relieve a number of problems in post menopausal women including 3 hot flashes, osteoporosis, and decline in cognitive function; reduce cholesterol and triglycerides in plasma; improve symptoms of hypertension; and reduce 2 abdominal fat accumulation.5,6,7 1 Why Did Nestlé Purina 0 Control Isoflavones* Choose Isoflavones? *P<0.01 for Control vs. Isoflavones Soy isoflavones provide a number of benefits for managing dogs with obesity, and reducing rebound effects after weight loss.
    [Show full text]
  • FOODINTEGRITY Ensuring the Integrity of the European Food Chain
    FOODINTEGRITY Ensuring the Integrity of the European food chain 613688: Collaborative Project Seventh Framework Programme KBBE.2013.2.4-01: Assuring quality and authenticity in the food chain Deliverable: 14.1 Title: Report on development of chemical and metabolomic markers of product integrity and stability along processing. Author(s): Baroni, María Verónica; Erban, Alexander; Kopka, Joachim; Wunderlin, Daniel Beneficiary(s): Food Integrity Consortia Date of preparation: September 21th 2017. Period covered: November-2016; August-2017 Status: version 1 Dissemination level PU Public X PP Restricted to other participants RE Restricted to a group specified by the consortium CO Confidential, only members of the consortium The project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement No. 613688. Deliverable 14.1, version 1, 21‐09‐2017 Deliverable 14.1 Report on development of chemical and metabolomic markers of product integrity and stability along processing. TABLE OF CONTENTS Page Nr. 1 Description of Deliverable 3 2 Achievement of the Deliverable 3 2.1 Chemical fractionation and profiling of seeds for the discovery of potential chemical markers by GC-MS (MPIMP). 3 2.1.1 Seed selection (EU market). 3 2.1.2 Fractionation scheme to evaluate chemical markers in seeds 4 2.1.3 Evaluation of chemical markers in seeds by GC-MS and chemometrics 5 2.2 Chemical fractionation and profiling of seeds, and bakery products containing seeds, for the discovery of potential chemical markers by LC-MS (CONICET-ICYTAC). 10 2.2.1 Seed sampling, extraction and analytical procedures (AR mark et).
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Applications of in Silico Methods to Analyze the Toxicity and Estrogen T Receptor-Mediated Properties of Plant-Derived Phytochemicals ∗ K
    Food and Chemical Toxicology 125 (2019) 361–369 Contents lists available at ScienceDirect Food and Chemical Toxicology journal homepage: www.elsevier.com/locate/foodchemtox Applications of in silico methods to analyze the toxicity and estrogen T receptor-mediated properties of plant-derived phytochemicals ∗ K. Kranthi Kumara, P. Yugandharb, B. Uma Devia, T. Siva Kumara, N. Savithrammab, P. Neerajaa, a Department of Zoology, Sri Venkateswara University, Tirupati, 517502, India b Department of Botany, Sri Venkateswara University, Tirupati, 517502, India ARTICLE INFO ABSTRACT Keywords: A myriad of phytochemicals may have potential to lead toxicity and endocrine disruption effects by interfering Phytochemicals with nuclear hormone receptors. In this examination, the toxicity and estrogen receptor−binding abilities of a QSAR modeling set of 2826 phytochemicals were evaluated. The endpoints mutagenicity, carcinogenicity (both CAESAR and ISS Toxicity models), developmental toxicity, skin sensitization and estrogen receptor relative binding affinity (ER_RBA) Nuclear hormone receptor binding were studied using the VEGA QSAR modeling package. Alongside the predictions, models were providing pos- Self−Organizing maps sible information for applicability domains and most similar compounds as similarity sets from their training Clustering and classification schemes sets. This information was subjected to perform the clustering and classification of chemicals using Self−Organizing Maps. The identified clusters and their respective indicators were considered as potential hotspot structures for the specified data set analysis. Molecular screening interpretations of models wereex- hibited accurate predictions. Moreover, the indication sets were defined significant clusters and cluster in- dicators with probable prediction labels (precision). Accordingly, developed QSAR models showed good pre- dictive abilities and robustness, which observed from applicability domains, representation spaces, clustering and classification schemes.
    [Show full text]
  • Issues in Environmental Science and Technology
    ISSUES IN ENVIRONMENTAL SCIENCE AND TECHNOLOGY EDITORS: R. E. HESTER AND R. M. HARRISON 12 ROYAL SOCIETY OF CHEMISTRY ISBN 0-85404-255-5 ISSN 1350-7583 A catalogue record for this book is available from the British Library @ The Royal Society of Chemistry 1999 All rights reserved Apart from any lair dealing for the purposes of research or private study, or criticism or review as permitted under the terms of the UK Copyright, Designs and Patents Act, 1988, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Societ}' of Chemistry, or in the case ofreprographic reproduction only in accordance with the terms of the licence.~ issued b}' the Cop}Tight Licensing Agenc}' in the UK, or in accordance Ilith the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the addre.~.~ printed on this page. Published by The Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge CB4 OWF, UK For further information see our web site,at www.rsc.org Typeset in Great Britain by Vision Typesetting, Manchester Printed and bound by Redwood Books Ltd., Trowbridge, Wiltshire Editors Ronald E. Hester, BSc, DSc(London), PhD(Cornell), FRSC, CChem Ronald E. Rester is Professor of Chemistry in the University of York. He was for short periods a research fellow in Cam bridge and an assistant professor at Cornell before being appointed to a lectureship in chemistry in Y orkin 1965.
    [Show full text]
  • Daidzein and Genistein Content of Cereals
    European Journal of Clinical Nutrition (2002) 56, 961–966 ß 2002 Nature Publishing Group All rights reserved 0954–3007/02 $25.00 www.nature.com/ejcn ORIGINAL COMMUNICATION Daidzein and genistein content of cereals J Liggins1, A Mulligan1,2, S Runswick1 and SA Bingham1,2* 1Medical Research Council Dunn Human Nutrition Unit, Hills Road, Cambridge, UK; and 2European Prospective Investigation of Cancer, University of Cambridge, Cambridge, UK Objective: To analyse 75 cereals and three soy flours commonly eaten in Europe for the phytoestrogens daidzein and genistein. Design: The phytoestrogens daidzein and genistein were extracted from dried foods, and the two isoflavones quantified after hydrolytic removal of any conjugated carbohydrate. Completeness of extraction and any procedural losses of the isoflavones 0 0 were accounted for using synthetic daidzin (7-O-glucosyl-4 -hydroxyisoflavone) and genistin (7-O-glucosyl-4 5-dihydroxyiso- flavone) as internal standards. Setting: Foods from the Cambridge UK area were purchased, prepared for eating, which included cooking if necessary, and freeze dried. Three stock soy flours were also analysed. Results: Eighteen of the foods assayed contained trace or no detectable daidzein or genistein. The soy flours were rich sources, containing 1639 – 2117 mg=kg. The concentration of the two isoflavones in the remaining foods ranged from 33 to 11 873 mg=kg. Conclusion: These analyses will supply useful information to investigators determining the intake of phytoestrogens in cereal products in order to relate intakes to potential biological activities. Sponsorship: This work was supported by the United Kingdom Medical Research Council, Ministry of Agriculture Fisheries and Food (contract FS2034) and the United States of America Army (contract DAMD 17-97-1-7028).
    [Show full text]
  • Medicinal Properties of Selected Asparagus Species: a Review Polo-Ma-Abiele Hildah Mfengwana and Samson Sitheni Mashele
    Chapter Medicinal Properties of Selected Asparagus Species: A Review Polo-Ma-Abiele Hildah Mfengwana and Samson Sitheni Mashele Abstract Asparagus species are naturally distributed along Asia, Africa, and Europe and are known to have numerous biological properties. This review article was aimed to provide an organized summary of current studies on the traditional uses, phy- tochemistry, and pharmacological and toxicological studies of Asparagus laricinus Burch., Asparagus africanus Lam., Asparagus officinalis L., Asparagus racemosus Willd., and Asparagus densiflorus (Kunth) Jessop to attain and establish new insights for further researches. Information used in this review was obtained from electronic database including PubMed central, Google scholars, Science direct, Scopus, and Sabinet. Based on the present findings, the existing literature still presents some breaches about the mechanism of action of various constituents of these plants, and their relation to other plant compounds in poly-herbal formulations, as well as their long-term use and safety. More in-depth studies are still needed for active compounds and biological activities of Asparagus laricinus, Asparagus africanus, and Asparagus densiflorus. Therefore, innumerable opportunities and possibilities for investigation are still available in novel areas of these plants for future research stud¬ies. It can be concluded that all selected Asparagus species have tremendous potential to improve human health and the pharmacological activities of these plants can be attributed to bioactive phytochemicals they possess. Keywords: Asparagaceae, Asparagus africanus lam., Asparagus densiflorus (kunth) Jessop, Asparagus laricinus Burch., Asparagus officinalis L., Asparagus racemosus Willd., pharmacological actions, phytochemistry 1. Introduction Historically, plants were used for numerous purposes for mankind in general, inter alia, feeding and catering, culinary spices, medicine, various forms of cosmetics, symbols in worship and for a variety of ornamental goods.
    [Show full text]
  • Mindy Goldman, MD Clinical Professor Dept
    Managing Menopause Medically and Naturally Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women’s Cancer Care Program, UCSF Breast Care Center and Women’s Health University of California, San Francisco I have nothing to disclose –Mindy Goldman, MD CASE STUDY 50 yr. old G2P2 peri-menopausal woman presents with complaints of significant night sweats interfering with her ability to sleep. She has mild hot flashes during the day. She has never had a bone mineral density test but her mother had a hip fracture at age 62 due to osteoporosis. Her 46 yr. old sister was diagnosed with breast cancer at age 43, treated with lumpectomy and radiation and currently is doing well. There is no other family history of cancer. Questions 1. Would you offer her MHT? 2. If yes, how long would you continue it? 3. If no, what would you offer for alternative treatments? 4. Would your treatment differ if you knew she had underlying heart disease? Is it safe? How long can I take it? What about Mymy Bones?bones? Will it protect my heart? MHT - 2015 What about my brain? Will I get breast cancer? What about my hot flashes? Menopausal Symptoms Hot flashes Night sweats Sleep disturbances Vaginal dryness/Sexual dysfunction Mood disturbances How to Treat Menopausal Symptoms Hormone therapy Alternatives to hormones Complementary and Integrative Techniques Prior to Women’s Health Initiative Hormone therapy primary treatment of menopausal hot flashes Few women would continue hormones past one year By 1990’s well known
    [Show full text]